secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axsome Therapeutics, Inc. (AXSM)
CIK:        0001579428
Form:       8-K
Filed at:   2024-02-20T23:59:59+00:00
Accession:  0000950170-24-016797
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axsome Q4 2023 net product revenue $71.5M (+193% YoY); net loss $98.7M; pipeline milestones on track
--------------------------------------------------------------------------------

- Total net product revenue $71.5M in Q4 2023 (+193% YoY); full year $204.9M (+309% YoY).
- Auvelity net sales $49.0M in Q4 ($130.1M FY); Sunosi $22.5M Q4 ($74.8M FY, +67% YoY).
- Net loss Q4 $98.7M ($2.08/share) vs $61.2M loss in Q4 2022; FY loss $239.2M ($5.27/share).
- NDA submissions for AXS-07 (migraine) and AXS-14 (fibromyalgia) expected 1H 2024; SYMPHONY topline Q1 2024.
- Cash $386.2M at Dec 31, 2023, up from $200.8M; sufficient to fund ops into cash flow positivity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1579428/000095017024016797/0000950170-24-016797-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1579428/000095017024016797/axsm-20240220.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-016797

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer